

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**


Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**



**FIG. 1**

FIG. 2A




FIG. 2B




FIG. 2C




FIG. 3A




FIG. 3B







FIG. 3C



FIG. 4A



**B**

Protein Tyrosine Kinase	Residue at Region A	Residue at Region B	Residue at Region C	Residue at Region D	Residue at Region E	Residue at Region F
JAK3	Pro906	Tyr904	Leu905	Met902	Ala966	Asp912
JAK2	Pro933	Tyr931	Leu932	Met929	Gly993	Asp939
JAK1	Pro948	Phe946	Leu947	Met944	Gly1008	Glu954
BTk	Ala478	Tyr476	Met477	Thr 474	Ser 538	Asn 484
SYK	Glu342	Met340	Ala341	Met338	Ser403	Lys348
HCK	Ala342	Phe340	Met341	Ala342	Ala403	Asp348
LYN	Ala323	Tyr321	Met322	Ala323	Ala384	Asp329
IRK	Ala1080	Leu1078	Met1079	Met1076	Gly1149	Ser1086

**FIG. 4B**

FIG. 5A




FIG. 5B




FIG. 5C




FIG. 5D




FIG. 5E




FIG. 6A




FIG. 6B




FIG. 6C







FIG. 6D






**FIG. 7A**



**FIG. 7B**



**FIG. 7C**



FIG. 7D1





FIG. 7D2





**FIG. 8A**

FIG. 8B1



FIG. 8B2







FIG. 9B






FIG. 10




FIG. 11




FIG. 12



FIG. 13A




FIG. 13B





FIG. 13C






FIG. 14




FIG. 15




FIG. 16






FIG. 17

FIG. 18A




A. Control

FIG. 18B



B. UVB

FIG. 18C



C. DDE9501+UVB

FIG. 19C




FIG. 19B



FIG. 19A





FIG. 20A



FIG. 20B



FIG. 20C








FIG. 21A




FIG. 21B




FIG. 21C




FIG. 22




FIG. 23





FIG. 24



**FIG. 25**

# WHI-P131 (60 mg/kg/day) - effects on GVHD development

## Cumulative proportion surviving

<u>Group</u>	<u>n</u>	<u>Cumulative proportion surviving</u>			<u>median survival (d)</u>	<u>Logrank p value</u>	
		<u>30</u>	<u>60</u>	<u>90</u>		vs. Control	vs. WHI-P131
CONTROL	51	90.2 ± 4.2	17.6 ± 5.3	2.0 ± 1.9	44		
WHI-P131	9	100 ± 0	77.8 ± 13.9	33.3 ± 15.7	82	0.0003	
WHI-P132	9	88.9 ± 10.5	11.1 ± 10.5	0 ± 0	44	0.485	
Methotrexate	16	93.8 ± 6.1	56.2 ± 12.4	25.0 ± 10.8	63.5	0.0009	0.356
Methotrexate + WHI-P131	13	100 ± 0	76.9 ± 11.7	61.5 ± 13.5	87	<0.0001	0.320
Cyclosporine A	15	73.3 ± 11.4	26.7 ± 11.4	13.3 ± 8.8	45	0.493	0.029
Cyclosporine A + WHI-P131	15	80.0 ± 10.3	33.3 ± 12.2	20.0 ± 10.3	51	0.198	0.067

Methotrexate vs.  
Methotrexate + WHI-P131  
0.062

FIG. 26






FIG. 27




FIG. 28




FIG. 29




FIG. 30




FIG. 31




FIG. 32




FIG. 33




FIG. 34






FIG. 35




FIG. 36




FIG. 37




FIG. 38




FIG. 39




FIG. 40




FIG. 41




FIG. 42